symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
EPIX,3.96,2.091254,54684,174639168,0,1.68-5.16,0.73,ESSA Pharma Inc.,USD,0001633932,CA29668H7085,29668H708,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.essapharma.com,"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.",Dr. David Ross Parkinson M.D.,Healthcare,CA,50,17783310962,999 West Broadway,Vancouver,BC,V5Z 1K5,3.9517,6.7517,https://financialmodelingprep.com/image-stock/EPIX.png,2015-03-13,False,False,True,False,False
